Kornimate/medical-research-clean huggingface dataset:
application of a training program for executive functions in a sample of egyptian children with learning disorder

Conditions: Learning Disorders; Executive Dysfunction

Summary: in recent years, significant progress has been made on ways to improve executive functions (ef) skills for school readiness involving direct ef training and classroom educational programs. due to the absence of a well-structured arabic program for ef training in children, the rationale of this study is to implement a comprehensive, evidence-based intervention program to help egyptian children with learning disorders to overcome their ef impairment. it uses the multimodality approach to help meet the needs of students with a variety of learning styles. the aim of this study is to adapt the combined form of the "executive functions training-elementary", and the "promoting executive function in the classroom" programs and its application in order to test its effectiveness in the rehabilitation of egyptian learning disordered children.

the study was conducted on 40 children with dyslexia and executive dysfunction attending unit of phoniatrics, otorhinolaryngology department, alexandria university. the results were compared before and after intervention. the "executive functions training-elementary" program is an evidence-based practice that targets executive function skills in the early elementary years by training students how to plan, execute, complete, and monitor tasks. it develops cognitive abilities and behavior control with classroom-related activities for varying ability levels. the "promoting executive function in the classroom" program helps to incorporate executive function processes (such as planning, organization, prioritizing, and self-checking) into the classroom curriculum. chapters provide effective strategies for learning by improving how to learn. data were collected and entered to the computer using (statistical package for social science) program for statistical analysis (version 21). data were entered as numerical or categorical, as appropriate. kolmogorov-smirnov test of normality revealed no significance in the distribution of the variables, so the parametric statistics was adopted. data were described using minimum, maximum, mean, standard deviation and 95% confidence interval of the mean. categorical variables were described using frequency and percentage. comparisons were carried out between two studied dependent normally distributed variables using paired t-test. comparisons were carried out between more than two independent normally distributed subgroups using one-way analysis of variance (anova) test. when f ratio of anova was significant levene test of homogeneity of variances was done, and if significant brown-forsythe robust test was adopted. post-hoc multiple comparisons was done using games-howell.

Eligibility criteria:
inclusion criteria: * children complaining of specific learning disorder and executive function deficits exclusion criteria: * brain damage, mentally retarded or history of fits or subclinical fits * hearing or visual impairment * psychic problems

Keywords: executive functions learning disorder children
safety and efficacy study of sublingual immunotherapy (slit) to treat house dust mite allergic rhinitis in adolescents and children

Conditions: Allergic Rhinitis Due to Dust Mite

Summary: the purpose of this study is to assess the efficacy of one dose of sublingual immunotherapy (slit) administered to children and adolescents as allergen-based tablets once daily over a period of 24 months over 3 years compared to placebo, for reduction of allergic rhinitis symptoms and rescue medication use.

after the screening period, the patients will be administered 300 ir house dust mite allergen based tablets or placebo, once a day, for a period of 36 months with two windows of 8 months and 6 months without treatment. the carry over effect will be evaluated after a treatment free follow up period of 24 months. an independent data monitoring committee will be constituted to evaluate the efficacy and safety data at the end of year 1 and year 3, and the post-treatment long-term efficacy data at the end of year 4.

Eligibility criteria:
inclusion criteria: * male or female outpatients, aged 5-17 years inclusive * history of house dust mite-related allergic rhinitis for at least 1 year requiring regular intake of symptomatic treatment(s) * sensitised to d. pteronyssinus and/or d. farinae (positive skin prick test with wheal diameter greater than 3 mm and specific ige level ≥ 0.7 ku/l) exclusion criteria: • co-sensitization associated with clinically relevant allergic rhinitis, sinusitis, conjunctivitis or asthma likely to significantly change the symptoms of the patient throughout the study (that means patient symptomatic to another allergen than house dust mites to which the patient will be exposed during the study, i.e. will notably be excluded * patients sensitised to cat or dog allergens and regularly exposed to these allergens * patients sensitised to aspergillus, cladosporium, alternaria * patients sensitised to parietaria , ragweed, or mugwort, if this allergen is endemic to the region
one session vs staged management of calcular obstructive jaundice

Conditions: Calcular Obstructive Jaundice; Gall Bladder Disease

Summary: to compare the outcomes between doing ercp and laparoscopic cholecystectomy in one session vs staged management

to compare the outcomes between 3 groups: in the 1st group we will do ercp then laparoscopic cholecystectomy in the same session, in the 2nd group we will do laparoscopic cholecystectomy then ercp in the same session in group 3 we will do staged management

Eligibility criteria:
inclusion criteria: * age from 18-70 year * combined cbd and gall stone * stone less than 1.5 cm * fit for surgery * no upper abdominal surgery exclusion criteria: * age \ 70 * unfit for surgery * stone more than 1.5 cm * upper abdominal surgery
serum fgf-23 and vitamin d deficiency

Conditions: Osteomalacia

Summary: we aimed to determine the effect of vitamin d replacement therapy on serum fgf-23 concentrations in vitamin d deficient women and to compare the fgf-23 concentrations of vitamin d deficient patients with healthy subjects and patients with genetically-determined hypophosphatemic rickets.

study group was composed of vitamin d deficient females (n =18, mean age 29.1±9.9 yrs), vitamin d sufficient healthy females (control group; n = 19, mean age 28.5±5.2 yrs) and patients with genetically-determined hypophosphatemic rickets (n=13, mean age 26.5±15.1 yrs). groups were compared for serum fgf-23, 1,25 dihydroxy vitamin d3, calcium, phosphate, bone turnover markers, intact parathyroid hormone and urinary excretion of calcium and phosphate. vitamin d deficient group was re-evaluated after a standard treatment regimen.

Eligibility criteria:
inclusion criteria: * serum 25ohd vitamin \<30 ng/ml for group 1 * serum 25ohd vitamin \>30 ng/ml for control group exclusion criteria: * receiving medication(s) affecting bone metabolism * history of gastrointestinal disease and malabsorption * history of renal and liver disease

Keywords: fibroblast growth factor 23 osteomalacia vitamin d
effect of endothelin-1 receptor blockade on circulating endothelial microparticles levels in patients with pulmonary hypertension

Conditions: Pulmonary Hypertension

Summary: pulmonary hypertension is a progressive and life threatening condition. it is characterized by severe remodeling of the pulmonary vessel wall, obstructive plexiform lesions, multi-focal thrombosis, and enhanced vasoconstriction. all of these characteristics contribute to increased pulmonary vascular resistance. circulating endothelial microparticles (emps) play an integral role in the pathogenesis and perpetuation of pulmonary hypertension. levels of emps are considered a reliable biological parameter of endothelial injury. we propose to assess the evolution of both circulating and pulmonary venous emps in patients with ph. assessments will be made before and after initiation of endothelin-1 (et-1) receptor blocker therapy, and correlated to their patterns with the changes in mean pap, the 6 minutes walking distance test, and circulating endothelin-1 values. measurements of the endothelial microparticle circulating levels (assessed by flow cytometry methods) will be made before, 1 month and 3 months after initiation of therapy.


Eligibility criteria:
inclusion criteria: * patient's + 18 years with suspected pre-capillary pulmonary hypertension * prescribed endothelial - 1 receptor blocker exclusion criteria: * currently taking endothelium-active vasodilator therapy. * hemoglobin and / or hematocrit level blood the lower normal limit. * left ventricle dysfunction (lvef \<50%) * lv end-diastolic pressure \> 15 mmhg) * recent history (\<3 months) of pulmonary embolism * liver failure or abnormal liver function tests; aortic or mitral regurgitation or stenosis * current medication with endothelin-1 receptor antagonist, prostacyclin analogues or type 5 phosphodiesterase inhibitors. * subjects with conditions known to be associated with an increase in circulating endothelial microparticle numers, such as chronic renal failure (creatinine clearance \< 50 ml/min/m2) acute coronary syndromes and uncontrolled system hypertension.

Keywords: to determine if there is a trans-pulmonary gradient in the levels of emps in patients with ph to determine if the emps measured at the pulmonary capillary wedge position correlates even more strongly with the severity of ph than the circulating levels to determine if ph therapy with et-1 receptor blocker will modify emps levels
evaluation of ezetimibe and atorvastatin coadministration versus atorvastatin or rosuvastatin monotherapy in japanese patients with hypercholesterolemia (study p06027)(completed)

Conditions: Primary Hypercholesterolemia

Summary: the purpose of this study is to evaluate the efficacy and safety of atorvastatin 10 mg and ezetimibe 10 mg coadministration in japanese participants with hypercholesterolemia whose low-density lipoprotein (ldl)-cholesterol levels have not reached the lipid management target value with atorvastatin 10 mg alone, versus increasing the dose of atorvastatin to 20 mg or changing to rosuvastatin 2.5 mg.


Eligibility criteria:
inclusion criteria: * atorvastatin 10 mg monotherapy for 4 weeks or longer before the start of the 4-week washout and low density lipoprotein-cholesterol (ldl-c) levels that had not reached the following lipid management target values during treatment: category i (low-risk group) with no other risk factors - ldl-c \<160 mg/dl; category ii (mid-risk group) with 1-2 risk factors other than ldl-c levels - ldl-c \<140 mg/dl; category iii (high-risk group) with 3 or more other risk factors - ldl-c \<120 mg/dl; and for participants with history of coronary artery disease - ldl-c \<100 mg/dl. * outpatient men or women, age 20 years and older exclusion criteria: * fasted triglyceride level at the start of washout or treatment period exceeding 400 mg/dl. * homozygous familial hypercholesterolemia. * creatine phosphokinase (cpk) \>2 times the upper limit of normal (x uln) at start of washout or treatment period. * glycosylated hemoglobin (hba1c) \>=8％ at start of washout or treatment period. * severe hepatic function disorder, or aspartate aminotransferase (ast) or alanine aminotransferase (alt) \>2x uln at start of washout or treatment period. * hypersensitivity to ezetimibe, atorvastatin, or rosuvastatin tablets. * pregnant or lactating * discontinued use of atorvastatin 10 mg for less than 4 weeks at start of treatment period (however, if participant had taken atorvastatin 10 mg before the test conducted at the start of the observation period, a period of discontinuation of 27 days is allowed.) * cyclosporine treatment * hyperlipidemia associated with hypothyroidism, obstructive gall bladder or biliary disease, chronic renal failure, and/or pancreatitis. * hyperlipidemia associated with drug administration that causes adverse serum lipid effects. * participation in a clinical study within 4 weeks of washout * cancer or cancer history within previous 5 years, except for successfully treated basal cell carcinoma of the skin.
changes in myocardial biomechanics and early short-term doxycycline therapy in patients with primary anterior stemi

Conditions: Vascular Diseases; Cardiovascular Diseases; Acute Myocardial Infarction

Summary: the purpose of the study is to investigate the changes of myocardial biomechanics and efficacy of doxycycline in patients with primary anterior stemi.

it is known that mmps (matrix metalloproteinases) take part in myocardial remodeling, which lead to the adverse remodeling of left ventricular. doxycycline inhibiting mmps and it help to prevent collagen degradation and following lv (left ventricular) dilatation. some experimental studies on rat models have suggested an anti-remodeling effect of doxycycline in myocardial infarction by means of decrease in activity of mmps-2 and recovery of contractile function of myocardium. the clinical trial was performed at 2013 (d.antoniucci), but it was a single study and confirmed theoretical and experimental background. the study is randomized, opened, controlled. 45 patients with the first anterior stemi will be enrolled. on admission all patients will receive reperfusion therapy during the first 24 h. patients will be randomized by the open envelope method and after that some of the participants will be on doxycycline (100 mg b.i.d. for 7 days) in addition to routine medical therapy for stemi, but other will be on routine medical therapy of stemi. after that they will have echocardiography at 3-d, 7-th, 14-th days and 6 month after stemi. the investigators will evaluate left ventricular function of these patients by routine and speckle-tracking echocardiography, incidence of cardiovascular end points (death, recurrent myocardial infarction, angina, heart failure, stroke) and their combinations, also the investigators will take blood samples to assess metalloproteinases (mmps) and other biomarkers.

Eligibility criteria:
inclusion criteria: * age ≥ 18 and ≤ 75 years at time of randomization (18 years and older) * st-elevation q wave myocardial infarction * term admission to an intensive care unit (icu) in the first 24 hours of onset * the reperfusion of the infarct-related coronary artery is not later than 24 hours after the initial onset of acute transmural myocardial infarction * written the informed consent to participate in research exclusion criteria: * atrial fibrillation, a permanent form * valvular heart disease * severe comorbidity * acute heart failure according to the killip classification iv fc (functional class) * history of chronic heart failure (nyha iii-iv) * poor image quality for echocardiography * sinus bradycardia - heart rate of under 50 beats per minute, interventricular conduction delay (qrs \> 0,11 s.) and atrioventricular block ii-iii degree

Keywords: stemi, adverse lvr (left ventricular remodeling), mmps, doxycycline
prevention of diverticulitis by taking a daily probiotic

Conditions: Acute Diverticulitis

Summary: there is evidence to show that daily probiotic lactobacillus casei shirota (lcs) in the form of yakult fermented milk supports a healthy balanced population of "friendly" gut bacteria. this, coupled with evidence from four european trials showing probiotic benefit for recurrent diverticulitis and an understanding of how the disease develops, indicates that lcs may also be beneficial. the investigators plan to undertake a pilot study investigating whether consumption of once daily probiotic lcs as yakult fermented milk would help either prevent attacks of diverticulitis completely or significantly reduce frequency of attacks. subjects will be recruited from surrey primary care units and will be closely monitored for 12 months whilst being supplied with a daily dose of for the full 12 months to see if this improves gut health.

because dietary fibre, obesity and diabetes are all confounding factors that influence the frequency and severity of attacks of diverticulitis, the research project will take account of this by: 1. monitoring dietary fibre using a diet diary 2. measurement of height and weight to determine bmi 3. screening for undiagnosed diabetes and pre-diabetes as well as keeping a diet diary, subjects will be asked to keep a general health diary, and to complete gut health questionnaires at start, 6 months and 12 months.

Eligibility criteria:
inclusion criteria: 1. a history of two episodes of uad treated with antibiotics in the last five years. 2. diverticulosis confirmed by colonoscopy, barium enema, uss, ct or mri imaging or at surgery. 3. agreement to consume one bottle of yakult daily for 12 months 4. availability of space in the domestic refrigerator for storage of yakult units 5. able to access depot (local primary care premises or chemist) to collect regular supplies of yakult 6. able to cope with keeping a diary etc. 7. willing to take yakult supplies and a cold bag on holiday to ensure as near as possible continuous daily doses (certainly never more than one week break as lactobacilli casei will persist in the human gut for at least one week 8. capable of giving informed consent 9. aged ≥ 50 and ≤ 75 years at commencement of trial. exclusion criteria: 1. recent history of peptic ulcer 2. chronic renal insufficiency 3. ongoing or past major diverticulitis complications 4. any serious debilitating illness (cancers, cardiovascular disease etc. but not dm) 5. dementias or memory problems 6. regular probiotic consumption over the past year. 7. undergoing immunosuppressive therapy or treatment 8. lactose intolerance or intolerance to dairy products 9. immunosuppressed patients

Keywords: probiotic lactobacillus colonic diseases dietary fibre
"becoming parents": a hospital-community partnership

Conditions: Expectant Couples

Summary: the proposed of this study is to determine if an intervention, known as the "becoming parents" programme, is more effective in improving the mental health, marital relationship and parental competence of expectant couples in a chinese community.

transition to parenthood is potentially a stressful life event for many new parents, which, if not properly managed, could have adverse effects on their mental health, marital satisfaction, and parent-child relationships. the proposed programme, "becoming parents", aims to turn the challenges of the transition into opportunities of learning and support for these parents. building on our experience of instituting a pioneering programme to support new fathers prenatally, "becoming parents" has an extra component of support for new parents in the postnatal period using trained volunteers from the community networks. through "becoming parents", seamless antenatal-postnatal care based on a hospital-community partnership will be provided to 125 expectant couples in a target community which is known for its high risks for postnatal depression, child abuse and intimate partner violence. in addition to addressing the health promotional needs of the target community, "becoming parents" will also illustrate how a community's capacity for health promotion can be maximized through the collaboration of healthcare providers and network of community partners in helping couples function more optimally during their transition to parenthood.

Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. expectant couples with the pregnant women attending antenatal clinic in princess margaret hospital before 20 weeks of gestation. exclusion criteria: 1. expected couples who are unable to communicate in cantonese, putonghua or english. 2. multiple pregnancy

Keywords: depression marital relationship parental competence
a study of shr-3821 injection in subjects with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: this is an open label, multi-center, multiple dose phase i study to evaluate the safety, tolerability, pharmacokinetics and efficacy of shr-3821 injection in subjects with advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. voluntary participation and written informed consent. 2. 18-75 years older, no gender limitation. 3. eastern cooperative oncology group (ecog) score: 0-1. 4. with a life expectancy ≥ 3 months. 5. pathologically diagnosed advanced solid tumor. 6. be able to provide fresh or archived tumour tissue. 7. at least one measurable lesion according to recist v1.1. 8. adequate bone marrow reserve and organ function. 9. contraception is required during the trial. exclusion criteria: 1. meningeal metastasis history or clinical symptoms of central nervous system metastasis. 2. uncontrollable tumor-related pain. 3. uncontrolled pleural effusion, pericardial effusion, or abdominal effusion with clinical symptoms. 4. received systemic antitumor therapy before the first dose. 5. treated with similar target therapy as shr-3821 before the first dose. 6. received systemic anticancer treatments 4 weeks prior to the initiation of the study treatment. 7. unresolved ctcae 5.0\>=grade 2 toxicities from previous anticancer therapy. 8. current or history of ild. 9. active severe digestive disease. 10. previous or co-existing malignancies. 11. history of severe hypersensitivity reactions to either the drug substances or inactive ingredients of shr-3821. 12. active hepatitis b or active hepatitis c. 13. other inappropriate situation considered by the investigator.
radiotherapy treatments for neoplasms of the limbs

Conditions: Bone Neoplasms; Bone Metastases

Summary: in this observational study patients treated at european institute of oncology with radiotherapy to limbs will be included

approximately 60% of patients with neoplasms receive radiotherapy as part of their oncological treatment. various primary tumors as well as metastases of various origins can be localized in the upper or lower limbs. patients with such neoplastic localizations will therefore receive radiotherapy treatment possibly associated with other systemic or surgical treatments. treatment choice is usually established following multidisciplinary discussions, based on disease characteristics and stage, concurrent pathologies and pharmacological treatments, patient preferences, and functional aspects. data collection related to radiotherapy plays a crucial role in understanding various clinical aspects of the treatment itself. the availability of data from an increasing number of patients will allow the identification of clinical situations or technical parameters of radiotherapy correlated with treatment tolerance and effectiveness, aiming to identify the best treatment for these oncological pathologies. this project aims to collect data related to radiotherapy treatments for primary or secondary neoplasms localized in the upper or lower limbs for scientific dissemination with the goal of establishing the basis for evaluating achieved results over time, and deriving from these elements useful for guiding the most effective treatment strategies and appropriate operational protocols.

Eligibility criteria:
inclusion criteria: 1. patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the upper and lower limbs for: primary bone tumors, primary soft tissue tumors, primary tumors of the cardio-circulatory system, primary tumors of the lymphatic system, primary tumors of the nervous system and skin, secondary metastases from various origins localized in that district. 2. signed informed consent exclusion criteria: 1. radiotherapy in districts other than limbs.